Rates of 30-Day and 90-Day Readmission Between Genotype-Optimal and Genotype-Suboptimal Antiplatelet Therapy Prescribing After Percutaneous Coronary Intervention-Reference-Cited by-同舟云学术

Rates of 30-Day and 90-Day Readmission Between Genotype-Optimal and Genotype-Suboptimal Antiplatelet Therapy Prescribing After Percutaneous Coronary Intervention

Published:2023-09 Issue: Volume:202 Page:218-222
ISSN:0002-9149
Container-title:The American Journal of Cardiology
language:en
Short-container-title:The American Journal of Cardiology

Author:

Cheng Kevin K.,San Andres Christian,Salam Emen,Han Jin,Lee James C.^ORCID

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference20 articles.

1. Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects;Hulot;Blood,2006

2. Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10 + 12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients;Giusti;Pharmacogenet Genomics,2007

3. Bleeding and stent thrombosis on P2Y12-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention;Aradi;Eur Heart J,2015

4. Prasugrel versus clopidogrel in patients with acute coronary syndromes;Wiviott;N Engl J Med,2007

5. Ticagrelor versus clopidogrel in patients with acute coronary syndromes;Wallentin;N Engl J Med,2009

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dual Antiplatelet Therapy in Percutaneous Coronary Intervention: Exploring the Role of Genotype-Guided Therapy in Reducing Readmission Rates;The American Journal of Cardiology;2023-09